Vidaroo Competitors

Vidaroo (CNSX:VIDA) and Canopy Rivers (TSE:RIV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares Vidaroo and Canopy Rivers' top-line revenue, earnings per share and valuation.

Vidaroo has higher earnings, but lower revenue than Canopy Rivers.

Analyst Recommendations

This is a breakdown of current recommendations for Vidaroo and Canopy Rivers, as reported by MarketBeat.com.

Canopy Rivers has a consensus target price of C$4.00, suggesting a potential upside of 32.01%.

Profitability

This table compares Vidaroo and Canopy Rivers' net margins, return on equity and return on assets.

Summary

Canopy Rivers beats Vidaroo on 1 of the 1 factors compared between the two stocks.

Vidaroo (CNSX:VIDA) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares Vidaroo and Willow Biosciences Inc. (WLLW.TO)'s top-line revenue, earnings per share and valuation.

Vidaroo has higher earnings, but lower revenue than Willow Biosciences Inc. (WLLW.TO).

Analyst Recommendations

This is a breakdown of current recommendations for Vidaroo and Willow Biosciences Inc. (WLLW.TO), as reported by MarketBeat.com.

Willow Biosciences Inc. (WLLW.TO) has a consensus target price of C$2.75, suggesting a potential upside of 69.75%.

Profitability

This table compares Vidaroo and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Summary

Willow Biosciences Inc. (WLLW.TO) beats Vidaroo on 1 of the 1 factors compared between the two stocks.

Vidaroo (CNSX:VIDA) and MediPharm Labs Corp. (LABS.TO) (TSE:LABS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares Vidaroo and MediPharm Labs Corp. (LABS.TO)'s top-line revenue, earnings per share and valuation.

Vidaroo has higher earnings, but lower revenue than MediPharm Labs Corp. (LABS.TO).

Analyst Recommendations

This is a breakdown of current recommendations for Vidaroo and MediPharm Labs Corp. (LABS.TO), as reported by MarketBeat.com.

MediPharm Labs Corp. (LABS.TO) has a consensus target price of C$1.98, suggesting a potential upside of 204.62%.

Profitability

This table compares Vidaroo and MediPharm Labs Corp. (LABS.TO)'s net margins, return on equity and return on assets.

Summary

MediPharm Labs Corp. (LABS.TO) beats Vidaroo on 2 of the 2 factors compared between the two stocks.

Vidaroo (CNSX:VIDA) and Khiron Life Sciences Corp. (KHRN.V) (CVE:KHRN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares Vidaroo and Khiron Life Sciences Corp. (KHRN.V)'s top-line revenue, earnings per share and valuation.

Vidaroo has higher earnings, but lower revenue than Khiron Life Sciences Corp. (KHRN.V).

Analyst Recommendations

This is a breakdown of current recommendations for Vidaroo and Khiron Life Sciences Corp. (KHRN.V), as reported by MarketBeat.com.

Khiron Life Sciences Corp. (KHRN.V) has a consensus target price of C$1.20, suggesting a potential upside of 118.18%.

Profitability

This table compares Vidaroo and Khiron Life Sciences Corp. (KHRN.V)'s net margins, return on equity and return on assets.

Summary

Khiron Life Sciences Corp. (KHRN.V) beats Vidaroo on 1 of the 1 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and Vidaroo (CNSX:VIDA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings for Delta 9 Cannabis and Vidaroo, as provided by MarketBeat.com.

Delta 9 Cannabis currently has a consensus price target of C$1.24, suggesting a potential upside of 121.43%.

Profitability

This table compares Delta 9 Cannabis and Vidaroo's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Delta 9 Cannabis and Vidaroo's gross revenue, earnings per share (EPS) and valuation.

Vidaroo has lower revenue, but higher earnings than Delta 9 Cannabis.

Summary

Delta 9 Cannabis beats Vidaroo on 2 of the 2 factors compared between the two stocks.

Meta Growth Corp. (META.V) (CVE:META) and Vidaroo (CNSX:VIDA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Profitability

This table compares Meta Growth Corp. (META.V) and Vidaroo's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Meta Growth Corp. (META.V) and Vidaroo, as provided by MarketBeat.com.

Valuation & Earnings

This table compares Meta Growth Corp. (META.V) and Vidaroo's gross revenue, earnings per share (EPS) and valuation.

Vidaroo has lower revenue, but higher earnings than Meta Growth Corp. (META.V).

Summary

Meta Growth Corp. (META.V) beats Vidaroo on 1 of the 1 factors compared between the two stocks.